Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Goflikicept in Pediatric and Adolescent Participants With Familial Mediterranean Fever
NCT07880886Phase 3Not yet recruiting
- Sponsor
- R-Pharm
- Start
- Dec 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of goflikicept in Familial Mediterranean fever (FMF), sponsored by R-Pharm. Primary endpoints: Maximum serum concentration at Week 16 and Area under serum concentration-time curve at Week 16. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
goflikicept
03
Conditions
Familial Mediterranean fever (FMF)
Beyond the preview
Go deeper on NCT07880886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07880886.